Skip to main content
Stephen Vincent, MD, Neurology, Idaho Falls, ID, Mountain View Hospital

StephenGVincentMD, FAAN

Neurology • Idaho Falls, ID

Neuroimmunology/Multiple Sclerosis, Sleep Medicine

Associate Professor of Neurology, Idaho College of Osteopathic Medicine

Join to view full profile

Dr. Vincent is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Vincent's full profile

Already have an account?

Summary

  • Dr. Stephen Vincent is a neurologist in Idaho Falls, ID and is affiliated with Mountain View Hospital. He received his medical degree from Rush Medical College in Chicago, completed his internship at Loyola and returned to Rush for his neurological training. He has been in practice for more than 25 years. He specializes in neuroimmunology/multiple sclerosis, general neurology and sleep medicine.

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterResidency, Neurology, 1990 - 1993
  • Loyola University Medical Center
    Loyola University Medical CenterInternship, Internal Medicine, 1989 - 1990
  • Rush Medical College of Rush University Medical Center
    Rush Medical College of Rush University Medical CenterClass of 1989
  • University of Illinois at Urbana-Champaign
    University of Illinois at Urbana-ChampaignBS, Biology, 1985

Certifications & Licensure

  • WY State Medical License
    WY State Medical License 1996 - 2024
  • ID State Medical License
    ID State Medical License 1993 - 2024
  • IL State Medical License
    IL State Medical License 1989 - 1993
  • American Board of Psychiatry and Neurology Neurology
  • National Board of Physicians and Surgeons Neurology
  • National Board of Physicians and Surgeons Sleep Medicine

Publications & Presentations

PubMed

Abstracts/Posters

  • Postpartum Relapse After First On-study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years
    ...Stephen G. Vincent, MD, FAAN, ECTRIMS 2019, Stockholm, Sweden, 9/12/2019
  • Pregnancy Outcomes in Alemtuzumab-treated Patients With RRMS in the Phase 2 and 3 Clinical Development Program Over 16 Years
    ...Stephen G. Vincent, MD, FAAN, CMSC, Seattle Washington, 5/30/2019

Press Mentions

  • "It’s a Really Exciting Time to Be in the Contact Lens Industry”
    "It’s a Really Exciting Time to Be in the Contact Lens Industry”June 26th, 2021
  • Clinical and Experimental Optometry: A Truly International Journal
    Clinical and Experimental Optometry: A Truly International JournalOctober 26th, 2020

Committees

  • Chair, AAN - General Neurology Section 2008 - 2010

Research History

  • Safety MonitorVedolizumab-4006 An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications.2016 - 2019
  • Principal InvestigatorSTRATEGY - A multi-center, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from Tysabri® (natalizumab) to Tecfidera® (dimethyl fumarate).2015 - 2016
  • Principal InvestigatorSTRATIFY-2: John Cunningham Virus (JCV) Antibody Study of Multiple Sclerosis (MS) Patients With Relapsing Forms of MS Receiving Treatment With Tysabri (STRATIFY-2)2010 - 2015
  • Principal InvestigatorTYGRIS: TYSABRI® Global Observational Program in Safety2006 - 2014
  • Principal InvestigatorCAMMS323 – A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Bete-1a(Rebif) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis2008 - 2010
  • Principal InvestigatorCAMMS32400507 – A Phase 3 Randomized, Rater-and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low-and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Bete-1a(Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who have Relapsed On Therapy2008 - 2010
  • Sub investigatorTakeda 583 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose- Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects with Mild to Moderate Diabetic Peripheral Neuropathy2007 - 2008
  • Sub investigatorLilly B7A-MC-MBCV.1 2005-2006 A Cross-Sectional Study to Assess the Correlation Between the Quantitative Testing of Vibration Sensation and Nerve Conduction Studies of Peroneal and Tibial Nerves in Patients with Diabetes Mellitus2005 - 2006
  • Sub investigatorDainippon/Advance Biologics Study AS-3201-253 2005-2006 A Multicenter, Randomized, Double Blind, Placebo-Controlled Multiple Dose Study of the Efficacy and Safety of AS-3201 in Patients with Diabetic Sensorimotor Polyneuropathy (ranirestat)2005 - 2006
  • Sub investigatorLilly LY333531B7A-MC-MBBR Treatment of Peripheral Neuropathy in Patients with Diabetes A Phase 3 Pivotal Clinical Trial (Ruboxistaurin mesylate)2003 - 2006
  • Sub investigatorLilly LY333531B7A-MC-MBCW Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes (Ruboxistaurin mesylate)2003 - 2005

Hospital Affiliations

Dr. Stephen Vincent, Dr. Stephen Vincent, MD, Dr. S Vincent, Dr. Stephen G Vincent